Ixekizumab demonstrated superiority to adalimumab in achieving simultaneous joint and skin improvement in biologic-naive patients with active psoriatic arthritis, according to data from the phase 3b/4 SPIRIT Head-to-Head (H2H) study.
Researchers reported on the efficacy and safety of 300 mg or 150 mg secukinumab in managing axial manifestations in patients with psoriatic arthritis.
This study was conducted to assess the long-term clinical efficacy of etanercept in patients with early axial spondyloarthritis, who participated in the ESTHER trial.
Researchers assessed the sensitivity of Bath Ankylosing Spondylitis DiseaseActivity Index, Ankylosing Spondylitis Disease Activity Score and C-reactive protein against response to biologics in axial spondyloarthritis with coexistent fibromyalgia.
In a phase 3 study, researchers assessed the efficacy and safety of ixekizumab in patients with active nonradiographic axial spondyloarthritis.
Researchers assessed the effect of uveitis, psoriasis, and inflammatory bowel disease on disease activity and functional status in a population-based cohort of patients with axial spondyloarthritis.
Researchers assessed the effect of golimumab (TNFα blocker) and ustekinumab (IL-12/23 blocker) in improving depressive symptoms in patients with psoriatic arthritis.
Researchers reported on the efficacy of secukinumab in patients with psoriatic arthritis and nail psoriasis and other elements of the disease, including radiographic progression.
Findings showed somewhat higher rates of treated depression among patients with psoriatic arthritis exposed to corticosteroids alone or in combination with any other study drug and among patients exposed to interleukin inhibitors alone or in combination with DMARDs.
Tumor necrosis factor inhibitors slow radiologic progression when compared to other drug classes in ankylosing spondylitis.